Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESSO 45 | Robotic mastectomy shows superior complication rates vs conventional surgery

Han-Byoel Lee, MD, PhD, Seoul National University Hospital, Seoul, South Korea, discusses the emerging role of robotic and endoscopic breast surgery as minimally invasive alternatives to conventional mastectomy, highlighting the MARRES (NCT04585074) trial, which demonstrated superior complication rates compared to conventional approaches. Robotic mastectomy offers significant cosmetic advantages, including minimal scarring and healthier skin flaps, but oncologic safety remains to be established through large-scale randomized trials such as the ongoing ROM (NCT05490433) study. This interview took place at the 2026 European Society of Surgical Oncology (ESSO) Annual Meeting in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Transcript

So robotic breast surgery or minimal invasive surgeries including also the endoscopic breast surgeries is a, I think it’s a hot topic all around the world now, especially because in the US, they didn’t have approval for breast cancer surgeries until last year, so until December last year actually. So now it has been approved for breast surgeries all around the world, especially the single port system...

So robotic breast surgery or minimal invasive surgeries including also the endoscopic breast surgeries is a, I think it’s a hot topic all around the world now, especially because in the US, they didn’t have approval for breast cancer surgeries until last year, so until December last year actually. So now it has been approved for breast surgeries all around the world, especially the single port system. It started, the first robotic case was presented back in 2015, but it has come a long way since then. In Korea, thanks to our insurance system and the reimbursement system through mostly private insurances, the private insurances are reimbursing the costs for the patients. We were able to perform a lot of the cases in numerous centers and what we try to do is to develop the evidence for oncologic safety as well as complications. And CompARE them to conventional nipple sparing mastectomies. Actually, I was one of the later, late surgeons that adopted robotic surgeries in Korea. I didn’t really see the cost effectiveness and especially if it would benefit the patients. I did my first case only in 2022 just because I wasn’t convinced that it would really be beneficial to our patients. But after performing a few cases, I could see where the advantage is. The biggest advantage is the scar, which is invisible in a lot of the cases. We don’t put any scars on the mound of the breast. And the scar is less than half of what we would use for a conventional mastectomy, especially if I would use for an inframammary fold incision. And also, the retraction we have to apply for our open conventional mastctomies, we’re putting mechanical injury to the skin flaps. When we use the robotic mastectomies techniques, the skin flabs are much, much healthier, so to speak. So the biggest evidence, the most solid evidence so far regarding the complications is the MARIS trial that was conducted in Korea, comparing conventional mastectomies versus endoscopic and robotic mastectomy, which was presented at the San Antonio Breast Cancer Symposium last year as a rapid oral presentation. MARIS trial was designed to show non-inferiority of robotic and endoscopic mastectomies compared to the conventional mastectomy. However, the results showed that it was superior in terms of complication rates. So it’s not published yet. Hopefully, we are publishing it soon. But anyways, it showed that robotic mastectomes and endoscope mastectoms can really help the patient in terms complications. What is not answered yet is the oncologic safety. Yes, there are some smaller trials that were presented by the European groups. However, we need some more large-scale randomized studies. So in Korea, there is a study called ROM, R-O-M, where we are enrolling 790 patients. They will be randomized to robotic mastectomies and conventional mastectomy. And they will be followed up for the primary endpoint of five-year disease-free survival. So we are at about 65 % enrollment right now in Korea. Hopefully, we will be able to show the oncologic safety of performing a robotic mastectomy in our patients also. Now, I really enjoy performing robotic mastctomies for our patients, for the selected patients, of course, because the patients have less pain. They feel better postoperatively. And also, I feel confident that I got all the breast tissue in the very corners that may be very difficult at times through conventional mastectomies. However, we do have to be careful in not going too much in that direction. I see some trends in parts of Asia and also in Korea where the younger generation are trying to do a lot of the surgeries with the robotic approach when we can just do a simple breast conserving surgery or breast conserver surgery using oncoplastic techniques. And also, it can be done with a very small incision through conventional mastectomies, especially in those with very small breasts. So, I would, what we’re trying to do in Korea, we do have a study group called the Korea BSG, Korea Robotic and Endoscopic Breast Surgery Study Group, where we’re trying to develop evidence and also provide education in the selection of patients that would actually benefit from these robotic and endoscopic approaches. So, going to your fourth question, what I would like to say is that the best candidates for robotic mastectomies is moderate-sized breasts. If the patients have, have cytosis, very large breasts, there is a higher chance of complications. And also, the angle of the robots and where it can REACH in the breast can be a little different for the larger breasts. For the very small breasts, I mentioned earlier, it doesn’t really, I don’t seem to, I don’ think there’s like, really, evident advantages for our patients compared to conventional nipple sparing mastectomies in these cases. So, I wouldn’t say that they would, robotics would be better for these patients. Middle-sized breasts, just regular, the, the, the average-sized breast and middle-sized breasts would be the best candidates. And also, obviously, those, the candidates for nipple sparing mastectomy where we can spare all the skin and also the nipple. So, that said, I would, I would urge a lot of the breast surgeons around the world to actually look into this method for nipple sparing mastectomies, especially. If you do have access to the robotic system in your institution, try to get a session, get the education. There are numerous workshops around the word educating robotic and endoscopic approaches. So, participate in those workshops. And, the learning curve is very steep and short. For me, it was about 10 cases, less than 10 cases. Now, I do a robotic mastectomy from induction of anesthesia to when I exit the OR for our reconstruction team to come in. So, it’s between an hour and a half and two hours. So, it’s, it’s a fairly easy procedure when you get used to it and you get to, you get use to it very quick. So, for the right selected patients, it will really benefit the patients and you, of course, because of the ergonomics. So, I think you should really look into the options and learning the technique.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.

Read more...

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.